Details of the Drug

General Information of Drug (ID: DMAI7ZV)

Drug Name
Diltiazem
Synonyms
Acalix; Adizem; Aldizem; Anoheal; Cardil; Cardizem; Citizem; Dilacor; Dilcontin; Dilren; Diltia; Diltiazemum; Dilticard; Diltzac; Dilzen; Endrydil; Viazem; Cardizen LA; Incoril AP; Tiazac Tildiem; Tiazac XC; Adizem (TN); Altiazem (TN); Angiozem (TN); Angizem (TN); Angizem CD (TN); Apo-Diltiaz; Cardizem (Hydrochloride); Cardizem (TN); Cartia XT (TN); Dilacor-XR; Dilatam (TN); Dilatem (TN); Dilcardia (TN); Dilcontin SR (TN); Dilt-cd; Dilta-Hexal; Diltelan (TN); Diltiazem (INN); Diltiazem [INN:BAN]; Diltiazemum [INN-Latin]; Diltime (TN); Dilzem (TN); Dyalec (TN); Filazem (TN); Herben (TN); Nu-Diltiaz; Progor (TN); RG 83606 (Hydrochloride); Surazem (TN); Tiamate (TN); Tiazac (TN); Tiazac XC (TN); Tildiem (TN); Vasmulax (TN); Viazem (TN); Zandil (TN); Zemtrial (TN); D-cis-Diltiazem; MK-793 (Malate); [(2S,3S)-5-(2-dimethylaminoethyl)-2-(4-methoxyphenyl)-4-oxo-2,3-dihydro-1,5-benzothiazepin-3-yl] acetate; Acetic acid (2S,3S)-5-(2-dimethylamino-ethyl)-2-(4-methoxy-phenyl)-4-oxo-2,3,4,5-tetrahydro-benzo[b][1,4]thiazepin-3-yl ester; (+)-cis-5-[2-(dimethylamino)ethyl]-2,3-dihydro-3-hydroxy-2-(p-methoxyphenyl)-1,5-benzothiazepin-4(5H)-one acetate ester; (2S,3S)-5-(2-(dimethylamino)ethyl)-2-(4-methoxyphenyl)-4-oxo-2,3,4,5-tetrahydrobenzo[b][1,4]thiazepin-3-yl acetate; (2S,3S)-5-[2-(dimethylamino)ethyl]-2-(4-methoxyphenyl)-4-oxo-2,3,4,5-tetrahydro-1,5-benzothiazepin-3-yl acetate; (2S,3S)-5-[2-(dimethylamino)ethyl]-2-[4-(methyloxy)phenyl]-4-oxo-2,3,4,5-tetrahydro-1,5-benzothiazepin-3-yl acetate; (2S-cis)-3-(acetyloxy)-5-[2-(dimethylamino)ethyl]-2,3-dihydro-2-(4-methoxyphenyl)-1,5-benzothiazepin-4(5H)-one
Indication
Disease Entry ICD 11 Status REF
Hypertension BA00-BA04 Approved [1], [2]
Therapeutic Class
Antihypertensive Agents
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 414.5
Topological Polar Surface Area (xlogp) 3.1
Rotatable Bond Count (rotbonds) 7
Hydrogen Bond Donor Count (hbonddonor) 0
Hydrogen Bond Acceptor Count (hbondacc) 6
ADMET Property
BDDCS Class
Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 1: high solubility and high permeability [3]
Bioavailability
The bioavailability of drug is 40% [4]
Clearance
The sytemic clearance of drug is 65 L/h [5]
Elimination
Due to its extensive metabolism, only 2% to 4% of the unchanged drug can be detected in the urine [4]
Half-life
The concentration or amount of drug in body reduced by one-half in 3.0 - 4.5 hours [4]
Metabolism
The drug is metabolized via the CYP3A4 [6]
MRTD
The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 19.29908 micromolar/kg/day [7]
Unbound Fraction
The unbound fraction of drug in plasma is 0.18% [8]
Vd
The volume of distribution (Vd) of drug is 305 L [5]
Chemical Identifiers
Formula
C22H26N2O4S
IUPAC Name
[(2S,3S)-5-[2-(dimethylamino)ethyl]-2-(4-methoxyphenyl)-4-oxo-2,3-dihydro-1,5-benzothiazepin-3-yl] acetate
Canonical SMILES
CC(=O)O[C@@H]1[C@@H](SC2=CC=CC=C2N(C1=O)CCN(C)C)C3=CC=C(C=C3)OC
InChI
InChI=1S/C22H26N2O4S/c1-15(25)28-20-21(16-9-11-17(27-4)12-10-16)29-19-8-6-5-7-18(19)24(22(20)26)14-13-23(2)3/h5-12,20-21H,13-14H2,1-4H3/t20-,21+/m1/s1
InChIKey
HSUGRBWQSSZJOP-RTWAWAEBSA-N
Cross-matching ID
PubChem CID
39186
ChEBI ID
CHEBI:101278
CAS Number
56209-45-1
DrugBank ID
DB00343
TTD ID
D0OB1J
VARIDT ID
DR00656
INTEDE ID
DR0509
ACDINA ID
D00200

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Voltage-gated calcium channel alpha-2/delta-1 (CACNA2D1) TTFK1JQ CA2D1_HUMAN Blocker [9]

Drug Transporter (DTP)
DTP Name DTP ID UniProt ID MOA REF
P-glycoprotein 1 (ABCB1) DTUGYRD MDR1_HUMAN Substrate [10]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Cytochrome P450 3A4 (CYP3A4)
Main DME 		DE4LYSA CP3A4_HUMAN Substrate [11]
Cytochrome P450 2D6 (CYP2D6)
Main DME 		DECB0K3 CP2D6_HUMAN Substrate [12]
Cytochrome P450 2C9 (CYP2C9) DE5IED8 CP2C9_HUMAN Substrate [12]
Mephenytoin 4-hydroxylase (CYP2C19) DEGTFWK CP2CJ_HUMAN Substrate [13]
Cytochrome P450 3A5 (CYP3A5) DEIBDNY CP3A5_HUMAN Substrate [14]
Cytochrome P450 2C8 (CYP2C8) DES5XRU CP2C8_HUMAN Substrate [15]
Cytochrome P450 3A7 (CYP3A7) DERD86B CP3A7_HUMAN Substrate [16]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Hypertension
ICD Disease Classification BA00-BA04
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Voltage-gated calcium channel alpha-2/delta-1 (CACNA2D1) DTT CACNA2D1 9.36E-01 -0.03 -0.13
Voltage-gated calcium channel alpha-2/delta-1 (CACNA2D1) DTT CACNA2D1 2.81E-05 -0.15 -0.68
P-glycoprotein 1 (ABCB1) DTP P-GP 1.24E-01 -4.12E-01 -4.68E-01
P-glycoprotein 1 (ABCB1) DTP P-GP 3.00E-02 -1.09E-02 -7.37E-02
Cytochrome P450 2C8 (CYP2C8) DME CYP2C8 2.41E-01 3.17E-02 2.29E-01
Cytochrome P450 2C8 (CYP2C8) DME CYP2C8 5.67E-01 5.11E-02 1.35E-01
Cytochrome P450 3A5 (CYP3A5) DME CYP3A5 6.74E-01 5.99E-02 7.30E-02
Cytochrome P450 3A5 (CYP3A5) DME CYP3A5 3.51E-01 1.59E-01 2.09E-01
Mephenytoin 4-hydroxylase (CYP2C19) DME CYP2C19 4.79E-03 1.32E-01 7.85E-01
Mephenytoin 4-hydroxylase (CYP2C19) DME CYP2C19 1.82E-01 -1.71E-02 -9.86E-02
Cytochrome P450 2D6 (CYP2D6) DME CYP2D6 8.01E-02 6.73E-02 3.36E-01
Cytochrome P450 2D6 (CYP2D6) DME CYP2D6 2.91E-04 1.41E-01 6.14E-01
Cytochrome P450 2C9 (CYP2C9) DME CYP2C9 7.33E-02 5.59E-02 2.99E-01
Cytochrome P450 2C9 (CYP2C9) DME CYP2C9 5.65E-03 -7.28E-02 -1.24E-01
Cytochrome P450 3A4 (CYP3A4) DME CYP3A4 2.13E-01 4.03E-02 2.50E-01
Cytochrome P450 3A4 (CYP3A4) DME CYP3A4 8.21E-02 8.17E-02 4.35E-01
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Diltiazem
DDI Drug Name DDI Drug ID Severity Mechanism Disease REF
Acebutolol DM0TI4U Major Increased risk of cardiac depression by the combination of Diltiazem and Acebutolol. Hypertension [BA00-BA04] [82]
Aliskiren DM1BV7W Moderate Decreased metabolism of Diltiazem caused by Aliskiren mediated inhibition of CYP450 enzyme. Hypertension [BA00-BA04] [83]
Bisoprolol DM3UZ95 Major Increased risk of cardiac depression by the combination of Diltiazem and Bisoprolol. Hypertension [BA00-BA04] [82]
Penbutolol DM4ES8F Major Increased risk of cardiac depression by the combination of Diltiazem and Penbutolol. Hypertension [BA00-BA04] [82]
Nebivolol DM7F1PA Major Increased risk of cardiac depression by the combination of Diltiazem and Nebivolol. Hypertension [BA00-BA04] [82]
Levamlodipine DM92S6N Moderate Decreased metabolism of Diltiazem caused by Levamlodipine mediated inhibition of CYP450 enzyme. Hypertension [BA00-BA04] [83]
Verapamil DMA7PEW Moderate Decreased metabolism of Diltiazem caused by Verapamil mediated inhibition of CYP450 enzyme. Hypertension [BA00-BA04] [84]
Amlodipine DMBDAZV Moderate Decreased metabolism of Diltiazem caused by Amlodipine mediated inhibition of CYP450 enzyme. Hypertension [BA00-BA04] [83]
Pindolol DMD2NV7 Major Increased risk of cardiac depression by the combination of Diltiazem and Pindolol. Hypertension [BA00-BA04] [82]
Labetalol DMK8U72 Major Increased risk of cardiac depression by the combination of Diltiazem and Labetalol. Hypertension [BA00-BA04] [82]
Felodipine DMOSW35 Moderate Decreased metabolism of Diltiazem caused by Felodipine mediated inhibition of CYP450 enzyme. Hypertension [BA00-BA04] [84]
⏷ Show the Full List of 11 DDI Information of This Drug
Coadministration of a Drug Treating the Disease Different from Diltiazem (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Methylergonovine DMBEX4O Moderate Decreased metabolism of Diltiazem caused by Methylergonovine mediated inhibition of CYP450 enzyme. Abortion [JA00] [85]
Repaglinide DM5SXUV Moderate Decreased metabolism of Diltiazem caused by Repaglinide mediated inhibition of CYP450 enzyme. Acute diabete complication [5A2Y] [86]
Pioglitazone DMKJ485 Moderate Decreased metabolism of Diltiazem caused by Pioglitazone mediated inhibition of CYP450 enzyme. Acute diabete complication [5A2Y] [87]
Ivosidenib DM8S6T7 Major Decreased metabolism of Diltiazem caused by Ivosidenib mediated inhibition of CYP450 enzyme. Acute myeloid leukaemia [2A60] [88]
Midostaurin DMI6E0R Moderate Decreased metabolism of Diltiazem caused by Midostaurin mediated inhibition of CYP450 enzyme. Acute myeloid leukaemia [2A60] [89]
Idarubicin DMM0XGL Moderate Decreased clearance of Diltiazem due to the transporter inhibition by Idarubicin. Acute myeloid leukaemia [2A60] [90]
Daunorubicin DMQUSBT Moderate Decreased clearance of Diltiazem due to the transporter inhibition by Daunorubicin. Acute myeloid leukaemia [2A60] [90]
Gilteritinib DMWQ4MZ Moderate Decreased clearance of Diltiazem due to the transporter inhibition by Gilteritinib. Acute myeloid leukaemia [2A60] [91]
Mitotane DMU1GX0 Moderate Increased metabolism of Diltiazem caused by Mitotane mediated induction of CYP450 enzyme. Adrenal cancer [2D11] [92]
Loratadine DMF3AN7 Moderate Decreased metabolism of Diltiazem caused by Loratadine mediated inhibition of CYP450 enzyme. Allergic/hypersensitivity disorder [4A80-4A8Z] [84]
Ivabradine DM0L594 Major Decreased metabolism of Diltiazem caused by Ivabradine mediated inhibition of CYP450 enzyme. Angina pectoris [BA40] [91]
Buspirone DMBS632 Moderate Decreased metabolism of Diltiazem caused by Buspirone mediated inhibition of CYP450 enzyme. Anxiety disorder [6B00-6B0Z] [93]
Alprazolam DMC7XDN Moderate Decreased metabolism of Diltiazem caused by Alprazolam mediated inhibition of CYP450 enzyme. Anxiety disorder [6B00-6B0Z] [84]
Methylphenobarbital DMDSWAG Moderate Increased metabolism of Diltiazem caused by Methylphenobarbital mediated induction of CYP450 enzyme. Anxiety disorder [6B00-6B0Z] [94]
Halazepam DMPFWO6 Moderate Decreased metabolism of Diltiazem caused by Halazepam mediated inhibition of CYP450 enzyme. Anxiety disorder [6B00-6B0Z] [84]
Chlordiazepoxide DMTN5XI Moderate Decreased metabolism of Diltiazem caused by Chlordiazepoxide mediated inhibition of CYP450 enzyme. Anxiety disorder [6B00-6B0Z] [84]
Clobazam - Lundbeck DMW1OQ0 Moderate Decreased metabolism of Diltiazem caused by Clobazam - Lundbeck mediated inhibition of CYP450 enzyme. Anxiety disorder [6B00-6B0Z] [84]
Promazine DMZAL7W Moderate Additive hypotensive effects by the combination of Diltiazem and Promazine. Appearance/behaviour symptom [MB23] [95]
Cilostazol DMZMSCT Major Decreased metabolism of Diltiazem caused by Cilostazol mediated inhibition of CYP450 enzyme. Arterial occlusive disease [BD40] [91]
Posaconazole DMUL5EW Moderate Decreased metabolism of Diltiazem caused by Posaconazole mediated inhibition of CYP450 enzyme. Aspergillosis [1F20] [96]
Budesonide DMJIBAW Moderate Decreased metabolism of Diltiazem caused by Budesonide mediated inhibition of CYP450 enzyme. Asthma [CA23] [97]
Aminophylline DML2NIB Moderate Decreased metabolism of Diltiazem caused by Aminophylline mediated inhibition of CYP450 enzyme. Asthma [CA23] [84]
Zileuton DMVRIC2 Minor Decreased metabolism of Diltiazem caused by Zileuton mediated inhibition of CYP450 enzyme. Asthma [CA23] [98]
Dalfopristin DM4LTKV Moderate Decreased metabolism of Diltiazem caused by Dalfopristin mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [99]
Clarithromycin DM4M1SG Moderate Decreased metabolism of Diltiazem caused by Clarithromycin mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [84]
Troleandomycin DMUZNIG Moderate Decreased metabolism of Diltiazem caused by Troleandomycin mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [84]
Telithromycin DMZ4P3A Moderate Decreased metabolism of Diltiazem caused by Telithromycin mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [100]
Pexidartinib DMS2J0Z Major Decreased metabolism of Diltiazem caused by Pexidartinib mediated inhibition of CYP450 enzyme. Bone/articular cartilage neoplasm [2F7B] [101]
Loperamide DMOJZQ9 Major Decreased clearance of Diltiazem due to the transporter inhibition by Loperamide. Bowel habit change [ME05] [102]
Talazoparib DM1KS78 Moderate Decreased clearance of Diltiazem due to the transporter inhibition by Talazoparib. Breast cancer [2C60-2C6Y] [103]
Ixabepilone DM2OZ3G Moderate Decreased metabolism of Diltiazem caused by Ixabepilone mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [104]
Lapatinib DM3BH1Y Moderate Decreased metabolism of Diltiazem caused by Lapatinib mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [105]
HKI-272 DM6QOVN Major Decreased metabolism of Diltiazem caused by HKI-272 mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [106]
LY2835219 DM93VBZ Moderate Decreased metabolism of Diltiazem caused by LY2835219 mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [107]
Esterified estrogens DM9KZDO Moderate Decreased metabolism of Diltiazem caused by Esterified estrogens mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [84]
Tucatinib DMBESUA Moderate Decreased metabolism of Diltiazem caused by Tucatinib mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [108]
Palbociclib DMD7L94 Moderate Decreased metabolism of Diltiazem caused by Palbociclib mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [91]
Quinestrol DMJ6H1Z Moderate Decreased metabolism of Diltiazem caused by Quinestrol mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [84]
Tamoxifen DMLB0EZ Moderate Decreased metabolism of Diltiazem caused by Tamoxifen mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [84]
Cabazitaxel DMPAZHC Moderate Decreased metabolism of Diltiazem caused by Cabazitaxel mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [109]
Toremifene DMQYUWG Moderate Decreased metabolism of Diltiazem caused by Toremifene mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [110]
Bosutinib DMTI8YE Major Decreased metabolism of Diltiazem caused by Bosutinib mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [111]
Estradiol DMUNTE3 Moderate Decreased metabolism of Diltiazem caused by Estradiol mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [84]
Grepafloxacin DMGLX0T Moderate Decreased metabolism of Diltiazem caused by Grepafloxacin mediated inhibition of CYP450 enzyme. Bronchitis [CA20] [112]
Sotalol DML60TN Major Increased risk of cardiac depression by the combination of Diltiazem and Sotalol. Cardiac arrhythmia [BC9Z] [82]
Atorvastatin DMF28YC Moderate Decreased metabolism of Diltiazem caused by Atorvastatin mediated inhibition of CYP450 enzyme. Cardiovascular disease [BA00-BE2Z] [113]
Macitentan DMP79A1 Moderate Decreased metabolism of Diltiazem caused by Macitentan mediated inhibition of CYP450 enzyme. Cardiovascular disease [BA00-BE2Z] [114]
Secobarbital DM14RF5 Moderate Increased metabolism of Diltiazem caused by Secobarbital mediated induction of CYP450 enzyme. Chronic insomnia [7A00] [92]
PF-04449913 DMSB068 Moderate Decreased metabolism of Diltiazem caused by PF-04449913 mediated inhibition of CYP450 enzyme. Chronic myelomonocytic leukaemia [2A40] [115]
Indacaterol DMQJHR7 Minor Decreased clearance of Diltiazem due to the transporter inhibition by Indacaterol. Chronic obstructive pulmonary disease [CA22] [116]
Phenylbutazone DMAYL0T Moderate Increased metabolism of Diltiazem caused by Phenylbutazone mediated induction of CYP450 enzyme. Chronic pain [MG30] [92]
Fidaxomicin DMFP6MV Minor Decreased clearance of Diltiazem due to the transporter inhibition by Fidaxomicin. Clostridium difficile enterocolitis [1A04] [117]
Irinotecan DMP6SC2 Moderate Decreased metabolism of Diltiazem caused by Irinotecan mediated inhibition of CYP450 enzyme. Colorectal cancer [2B91] [83]
Olopatadine DMKMWQG Moderate Additive CNS depression effects by the combination of Diltiazem and Olopatadine. Conjunctiva disorder [9A60] [118]
Levonorgestrel DM1DP7T Moderate Decreased metabolism of Diltiazem caused by Levonorgestrel mediated inhibition of CYP450 enzyme. Contraceptive management [QA21] [84]
Ulipristal DMBNI20 Minor Decreased metabolism of Diltiazem caused by Ulipristal mediated inhibition of CYP450 enzyme. Contraceptive management [QA21] [91]
Levobupivacaine DM783CH Moderate Decreased metabolism of Diltiazem caused by Levobupivacaine mediated inhibition of CYP450 enzyme. Corneal disease [9A76-9A78] [91]
Cocaine DMSOX7I Moderate Decreased metabolism of Diltiazem caused by Cocaine mediated inhibition of CYP450 enzyme. Corneal disease [9A76-9A78] [119]
Oxtriphylline DMLHSE3 Moderate Decreased metabolism of Diltiazem caused by Oxtriphylline mediated inhibition of CYP450 enzyme. Cough [MD12] [84]
Mifepristone DMGZQEF Moderate Decreased metabolism of Diltiazem caused by Mifepristone mediated inhibition of CYP450 enzyme. Cushing syndrome [5A70] [120]
Pasireotide DMHM7JS Moderate Increased risk of bradycardia by the combination of Diltiazem and Pasireotide. Cushing syndrome [5A70] [83]
Osilodrostat DMIJC9X Moderate Decreased metabolism of Diltiazem caused by Osilodrostat mediated inhibition of CYP450 enzyme. Cushing syndrome [5A70] [91]
Aminoglutethimide DMWFHMZ Moderate Increased metabolism of Diltiazem caused by Aminoglutethimide mediated induction of CYP450 enzyme. Cushing syndrome [5A70] [92]
Ivacaftor DMZC1HS Major Decreased metabolism of Diltiazem caused by Ivacaftor mediated inhibition of CYP450 enzyme. Cystic fibrosis [CA25] [91]
MK-8228 DMOB58Q Moderate Decreased metabolism of Diltiazem caused by MK-8228 mediated inhibition of CYP450 enzyme. Cytomegaloviral disease [1D82] [121]
Rivaroxaban DMQMBZ1 Moderate Decreased clearance of Diltiazem due to the transporter inhibition by Rivaroxaban. Deep vein thrombosis [BD71] [122]
Aprepitant DM053KT Moderate Decreased metabolism of Diltiazem caused by Aprepitant mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [123]
Sertraline DM0FB1J Moderate Decreased metabolism of Diltiazem caused by Sertraline mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [84]
Cyclobenzaprine DM1YBRM Moderate Decreased metabolism of Diltiazem caused by Cyclobenzaprine mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [84]
Fluoxetine DM3PD2C Moderate Decreased metabolism of Diltiazem caused by Fluoxetine mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [83]
Vilazodone DM4LECQ Moderate Decreased metabolism of Diltiazem caused by Vilazodone mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [124]
Nefazodone DM4ZS8M Moderate Decreased metabolism of Diltiazem caused by Nefazodone mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [125]
Selegiline DM6034S Moderate Additive hypotensive effects by the combination of Diltiazem and Selegiline. Depression [6A70-6A7Z] [126]
Isocarboxazid DMAF1NB Moderate Additive hypotensive effects by the combination of Diltiazem and Isocarboxazid. Depression [6A70-6A7Z] [126]
Escitalopram DMFK9HG Minor Decreased metabolism of Diltiazem caused by Escitalopram mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [127]
Tranylcypromine DMGB5RE Moderate Additive hypotensive effects by the combination of Diltiazem and Tranylcypromine. Depression [6A70-6A7Z] [126]
OPC-34712 DMHG57U Major Decreased metabolism of Diltiazem caused by OPC-34712 mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [128]
Phenelzine DMHIDUE Moderate Additive hypotensive effects by the combination of Diltiazem and Phenelzine. Depression [6A70-6A7Z] [126]
Trazodone DMK1GBJ Moderate Decreased metabolism of Diltiazem caused by Trazodone mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [84]
Mirtazapine DML53ZJ Moderate Decreased metabolism of Diltiazem caused by Mirtazapine mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [129]
Griseofulvin DMK54YG Moderate Increased metabolism of Diltiazem caused by Griseofulvin mediated induction of CYP450 enzyme. Dermatophytosis [1F28] [92]
Polatuzumab vedotin DMF6Y0L Moderate Decreased metabolism of Diltiazem caused by Polatuzumab vedotin mediated inhibition of CYP450 enzyme. Diffuse large B-cell lymphoma [2A81] [130]
[3H]estrone-3-sulphate DMGPF0N Moderate Decreased metabolism of Diltiazem caused by [3H]estrone-3-sulphate mediated inhibition of CYP450 enzyme. Discovery agent [N.A.] [119]
Zonisamide DM0DTF7 Moderate Decreased metabolism of Diltiazem caused by Zonisamide mediated inhibition of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [131]
Primidone DM0WX6I Moderate Increased metabolism of Diltiazem caused by Primidone mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [92]
Oxcarbazepine DM5PU6O Moderate Increased metabolism of Diltiazem caused by Oxcarbazepine mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [92]
Mephenytoin DM5UGDK Moderate Increased metabolism of Diltiazem caused by Mephenytoin mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [132]
Cenobamate DMGOVHA Moderate Increased metabolism of Diltiazem caused by Cenobamate mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [92]
Tiagabine DMKSQG0 Moderate Decreased metabolism of Diltiazem caused by Tiagabine mediated inhibition of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [84]
Stiripentol DMMSDOY Moderate Decreased metabolism of Diltiazem caused by Stiripentol mediated inhibition of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [91]
Fosphenytoin DMOX3LB Moderate Decreased metabolism of Diltiazem caused by Fosphenytoin mediated inhibition of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [132]
Clonazepam DMTO13J Moderate Decreased metabolism of Diltiazem caused by Clonazepam mediated inhibition of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [84]
Ethotoin DMXWOCP Moderate Decreased metabolism of Diltiazem caused by Ethotoin mediated inhibition of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [132]
Phenobarbital DMXZOCG Moderate Increased metabolism of Diltiazem caused by Phenobarbital mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [92]
Carbamazepine DMZOLBI Major Decreased metabolism of Diltiazem caused by Carbamazepine mediated inhibition of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [133]
Eslicarbazepine DMZREFQ Moderate Increased metabolism of Diltiazem caused by Eslicarbazepine mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [92]
Cannabidiol DM0659E Minor Decreased metabolism of Diltiazem caused by Cannabidiol mediated inhibition of CYP450 enzyme. Epileptic encephalopathy [8A62] [91]
Timolol DM3NXRU Major Increased risk of cardiac depression by the combination of Diltiazem and Timolol. Essential hypertension [BA00] [82]
Nicardipine DMCDYW7 Moderate Decreased metabolism of Diltiazem caused by Nicardipine mediated inhibition of CYP450 enzyme. Essential hypertension [BA00] [84]
Nadolol DMW6GVL Major Increased risk of cardiac depression by the combination of Diltiazem and Nadolol. Essential hypertension [BA00] [82]
Dantrolene DM1D8XY Moderate Increased risk of hyperkalemia by the combination of Diltiazem and Dantrolene. Fever [MG26] [134]
Bay 80-6946 DMLOS5R Moderate Decreased metabolism of Diltiazem caused by Bay 80-6946 mediated inhibition of CYP450 enzyme. Follicular lymphoma [2A80] [135]
Tazemetostat DMWP1BH Major Decreased metabolism of Diltiazem caused by Tazemetostat mediated inhibition of CYP450 enzyme. Follicular lymphoma [2A80] [136]
Solifenacin DMG592Q Moderate Decreased metabolism of Diltiazem caused by Solifenacin mediated inhibition of CYP450 enzyme. Functional bladder disorder [GC50] [137]
Mirabegron DMS1GYT Minor Decreased metabolism of Diltiazem caused by Mirabegron mediated inhibition of CYP450 enzyme. Functional bladder disorder [GC50] [138]
Tolterodine DMSHPW8 Moderate Decreased metabolism of Diltiazem caused by Tolterodine mediated inhibition of CYP450 enzyme. Functional bladder disorder [GC50] [139]
Miconazole DMPMYE8 Moderate Decreased metabolism of Diltiazem caused by Miconazole mediated inhibition of CYP450 enzyme. Fungal infection [1F29-1F2F] [96]
Ketoconazole DMPZI3Q Moderate Decreased metabolism of Diltiazem caused by Ketoconazole mediated inhibition of CYP450 enzyme. Fungal infection [1F29-1F2F] [96]
Cimetidine DMH61ZB Moderate Decreased metabolism of Diltiazem caused by Cimetidine mediated inhibition of CYP450 enzyme. Gastro-oesophageal reflux disease [DA22] [140]
Cisapride DMY7PED Major Decreased metabolism of Diltiazem caused by Cisapride mediated inhibition of CYP450 enzyme. Gastro-oesophageal reflux disease [DA22] [141]
Ripretinib DM958QB Moderate Decreased metabolism of Diltiazem caused by Ripretinib mediated inhibition of CYP450 enzyme. Gastrointestinal stromal tumour [2B5B] [111]
Avapritinib DMK2GZX Major Decreased metabolism of Diltiazem caused by Avapritinib mediated inhibition of CYP450 enzyme. Gastrointestinal stromal tumour [2B5B] [91]
Carteolol DMFMDOB Major Increased risk of cardiac depression by the combination of Diltiazem and Carteolol. Glaucoma [9C61] [82]
Metipranolol DMJMVKI Major Increased risk of cardiac depression by the combination of Diltiazem and Metipranolol. Glaucoma [9C61] [142]
Levobetaxolol DMSREPX Major Increased risk of cardiac depression by the combination of Diltiazem and Levobetaxolol. Glaucoma [9C61] [142]
Levobunolol DMTNFCQ Major Increased risk of cardiac depression by the combination of Diltiazem and Levobunolol. Glaucoma [9C61] [142]
Colchicine DM2POTE Major Decreased metabolism of Diltiazem caused by Colchicine mediated inhibition of CYP450 enzyme. Gout [FA25] [143]
Sulfinpyrazone DMEV954 Moderate Increased metabolism of Diltiazem caused by Sulfinpyrazone mediated induction of CYP450 enzyme. Gout [FA25] [92]
Eplerenone DMF0NQR Major Decreased metabolism of Diltiazem caused by Eplerenone mediated inhibition of CYP450 enzyme. Heart failure [BD10-BD1Z] [144]
Carvedilol DMHTEAO Major Increased risk of cardiac depression by the combination of Diltiazem and Carvedilol. Heart failure [BD10-BD1Z] [82]
Digoxin DMQCTIH Moderate Increased risk of atrioventricular block by the combination of Diltiazem and Digoxin. Heart failure [BD10-BD1Z] [145]
Boceprevir DMBSHMF Moderate Decreased metabolism of Diltiazem caused by Boceprevir mediated inhibition of CYP450 enzyme. Hepatitis virus infection [1E50-1E51] [146]
Simeprevir DMLUA9D Moderate Decreased clearance of Diltiazem due to the transporter inhibition by Simeprevir. Hepatitis virus infection [1E50-1E51] [147]
Telaprevir DMMRV29 Moderate Decreased metabolism of Diltiazem caused by Telaprevir mediated inhibition of CYP450 enzyme. Hepatitis virus infection [1E50-1E51] [146]
Rifampin DMA8J1G Major Increased metabolism of Diltiazem caused by Rifampin mediated induction of CYP450 enzyme. HIV-infected patients with tuberculosis [1B10-1B14] [148]
Rifapentine DMCHV4I Moderate Increased metabolism of Diltiazem caused by Rifapentine mediated induction of CYP450 enzyme. HIV-infected patients with tuberculosis [1B10-1B14] [92]
Procarbazine DMIK367 Moderate Additive hypotensive effects by the combination of Diltiazem and Procarbazine. Hodgkin lymphoma [2B30] [126]
Brentuximab vedotin DMWLC57 Moderate Decreased clearance of Diltiazem due to the transporter inhibition by Brentuximab vedotin. Hodgkin lymphoma [2B30] [149]
MK-1439 DM215WE Minor Decreased metabolism of Diltiazem caused by MK-1439 mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [150]
Delavirdine DM3NF5G Moderate Decreased metabolism of Diltiazem caused by Delavirdine mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [151]
Fosamprenavir DM4W9B3 Moderate Decreased metabolism of Diltiazem caused by Fosamprenavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [152]
Fostemsavir DM50ILT Moderate Decreased clearance of Diltiazem due to the transporter inhibition by Fostemsavir. Human immunodeficiency virus disease [1C60-1C62] [153]
Cobicistat DM6L4H2 Moderate Decreased clearance of Diltiazem due to the transporter inhibition by Cobicistat. Human immunodeficiency virus disease [1C60-1C62] [154]
Tipranavir DM8HJX6 Moderate Accelerated clearance of Diltiazem due to the transporter induction by Tipranavir. Human immunodeficiency virus disease [1C60-1C62] [155]
Efavirenz DMC0GSJ Moderate Increased metabolism of Diltiazem caused by Efavirenz mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [92]
Dolutegravir DMCZGRE Minor Decreased metabolism of Diltiazem caused by Dolutegravir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [156]
Etravirine DMGV8QU Moderate Decreased metabolism of Diltiazem caused by Etravirine mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [157]
Rilpivirine DMJ0QOW Moderate Decreased metabolism of Diltiazem caused by Rilpivirine mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [111]
Amprenavir DMLMXE0 Moderate Decreased metabolism of Diltiazem caused by Amprenavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [152]
Darunavir DMN3GCH Moderate Decreased metabolism of Diltiazem caused by Darunavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [158]
Maraviroc DMTL94F Moderate Decreased clearance of Diltiazem due to the transporter inhibition by Maraviroc. Human immunodeficiency virus disease [1C60-1C62] [159]
Ritonavir DMU764S Moderate Decreased metabolism of Diltiazem caused by Ritonavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [160]
Conivaptan DM1V329 Moderate Decreased metabolism of Diltiazem caused by Conivaptan mediated inhibition of CYP450 enzyme. Hypo-osmolality/hyponatraemia [5C72] [161]
Tolvaptan DMIWFRL Moderate Decreased metabolism of Diltiazem caused by Tolvaptan mediated inhibition of CYP450 enzyme. Hypo-osmolality/hyponatraemia [5C72] [162]
Retapamulin DM9JXB7 Minor Decreased metabolism of Diltiazem caused by Retapamulin mediated inhibition of CYP450 enzyme. Impetigo [1B72] [163]
Berotralstat DMWA2DZ Major Decreased clearance of Diltiazem due to the transporter inhibition by Berotralstat. Innate/adaptive immunodeficiency [4A00] [164]
Suvorexant DM0E6S3 Major Decreased metabolism of Diltiazem caused by Suvorexant mediated inhibition of CYP450 enzyme. Insomnia [7A00-7A0Z] [165]
Amobarbital DM0GQ8N Moderate Increased metabolism of Diltiazem caused by Amobarbital mediated induction of CYP450 enzyme. Insomnia [7A00-7A0Z] [92]
Eszopiclone DM8RZ9H Moderate Decreased metabolism of Diltiazem caused by Eszopiclone mediated inhibition of CYP450 enzyme. Insomnia [7A00-7A0Z] [166]
Flurazepam DMAL4G0 Moderate Decreased metabolism of Diltiazem caused by Flurazepam mediated inhibition of CYP450 enzyme. Insomnia [7A00-7A0Z] [84]
Triazolam DMETYK5 Moderate Decreased metabolism of Diltiazem caused by Triazolam mediated inhibition of CYP450 enzyme. Insomnia [7A00-7A0Z] [167]
Zaleplon DMGFWSM Moderate Decreased metabolism of Diltiazem caused by Zaleplon mediated inhibition of CYP450 enzyme. Insomnia [7A00-7A0Z] [84]
Propiomazine DMKY8V1 Moderate Additive hypotensive effects by the combination of Diltiazem and Propiomazine. Insomnia [7A00-7A0Z] [95]
Tasimelteon DMLOQ1V Moderate Decreased metabolism of Diltiazem caused by Tasimelteon mediated inhibition of CYP450 enzyme. Insomnia [7A00-7A0Z] [168]
ITI-007 DMUQ1DO Major Decreased metabolism of Diltiazem caused by ITI-007 mediated inhibition of CYP450 enzyme. Insomnia [7A00-7A0Z] [169]
Zolpidem DMWOSKJ Moderate Decreased metabolism of Diltiazem caused by Zolpidem mediated inhibition of CYP450 enzyme. Insomnia [7A00-7A0Z] [170]
Quazepam DMY4D87 Moderate Decreased metabolism of Diltiazem caused by Quazepam mediated inhibition of CYP450 enzyme. Insomnia [7A00-7A0Z] [84]
Estazolam DMZGXUM Moderate Decreased metabolism of Diltiazem caused by Estazolam mediated inhibition of CYP450 enzyme. Insomnia [7A00-7A0Z] [84]
Naloxegol DML0B41 Major Decreased metabolism of Diltiazem caused by Naloxegol mediated inhibition of CYP450 enzyme. Large intestine motility disorder [DB32] [91]
Pemigatinib DM819JF Major Decreased metabolism of Diltiazem caused by Pemigatinib mediated inhibition of CYP450 enzyme. Liver cancer [2C12] [91]
Testosterone DM7HUNW Moderate Decreased metabolism of Diltiazem caused by Testosterone mediated inhibition of CYP450 enzyme. Low bone mass disorder [FB83] [84]
Brigatinib DM7W94S Major Decreased metabolism of Diltiazem caused by Brigatinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [111]
Porfimer Sodium DM7ZWNY Moderate Increased risk of photosensitivity reactions by the combination of Diltiazem and Porfimer Sodium. Lung cancer [2C25] [171]
Lurbinectedin DMEFRTZ Major Decreased metabolism of Diltiazem caused by Lurbinectedin mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [172]
Osimertinib DMRJLAT Moderate Decreased metabolism of Diltiazem caused by Osimertinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [173]
Pralsetinib DMWU0I2 Moderate Decreased metabolism of Diltiazem caused by Pralsetinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [174]
Capmatinib DMYCXKL Moderate Decreased metabolism of Diltiazem caused by Capmatinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [175]
Selpercatinib DMZR15V Major Decreased metabolism of Diltiazem caused by Selpercatinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [91]
Halofantrine DMOMK1V Major Decreased metabolism of Diltiazem caused by Halofantrine mediated inhibition of CYP450 enzyme. Malaria [1F40-1F45] [176]
Chloroquine DMSI5CB Moderate Decreased metabolism of Diltiazem caused by Chloroquine mediated inhibition of CYP450 enzyme. Malaria [1F40-1F45] [111]
Hydroxychloroquine DMSIVND Moderate Decreased metabolism of Diltiazem caused by Hydroxychloroquine mediated inhibition of CYP450 enzyme. Malaria [1F40-1F45] [111]
Quinine DMSWYF5 Moderate Decreased metabolism of Diltiazem caused by Quinine mediated inhibition of CYP450 enzyme. Malaria [1F40-1F45] [111]
Idelalisib DM602WT Moderate Decreased metabolism of Diltiazem caused by Idelalisib mediated inhibition of CYP450 enzyme. Mature B-cell leukaemia [2A82] [177]
GDC-0199 DMH0QKA Major Decreased metabolism of Diltiazem caused by GDC-0199 mediated inhibition of CYP450 enzyme. Mature B-cell leukaemia [2A82] [111]
IPI-145 DMWA24P Moderate Decreased metabolism of Diltiazem caused by IPI-145 mediated inhibition of CYP450 enzyme. Mature B-cell leukaemia [2A82] [178]
Ibrutinib DMHZCPO Major Decreased metabolism of Diltiazem caused by Ibrutinib mediated inhibition of CYP450 enzyme. Mature B-cell lymphoma [2A85] [179]
Vincristine DMINOX3 Moderate Decreased metabolism of Diltiazem caused by Vincristine mediated inhibition of CYP450 enzyme. Mature B-cell lymphoma [2A85] [84]
Ponatinib DMYGJQO Moderate Decreased metabolism of Diltiazem caused by Ponatinib mediated inhibition of CYP450 enzyme. Mature B-cell lymphoma [2A85] [180]
Arry-162 DM1P6FR Moderate Decreased clearance of Diltiazem due to the transporter inhibition by Arry-162. Melanoma [2C30] [111]
Vemurafenib DM62UG5 Moderate Increased metabolism of Diltiazem caused by Vemurafenib mediated induction of CYP450 enzyme. Melanoma [2C30] [92]
Selumetinib DMC7W6R Major Decreased metabolism of Diltiazem caused by Selumetinib mediated inhibition of CYP450 enzyme. Melanoma [2C30] [181]
LGX818 DMNQXV8 Major Decreased metabolism of Diltiazem caused by LGX818 mediated inhibition of CYP450 enzyme. Melanoma [2C30] [182]
Dabrafenib DMX6OE3 Moderate Increased metabolism of Diltiazem caused by Dabrafenib mediated induction of CYP450 enzyme. Melanoma [2C30] [92]
Estrone DM5T6US Moderate Decreased metabolism of Diltiazem caused by Estrone mediated inhibition of CYP450 enzyme. Menopausal disorder [GA30] [84]
Dienestrol DMBSXI0 Moderate Decreased metabolism of Diltiazem caused by Dienestrol mediated inhibition of CYP450 enzyme. Menopausal disorder [GA30] [119]
Ethinyl estradiol DMODJ40 Moderate Decreased metabolism of Diltiazem caused by Ethinyl estradiol mediated inhibition of CYP450 enzyme. Menopausal disorder [GA30] [119]
Nitisinone DMVS9WQ Moderate Decreased metabolism of Diltiazem caused by Nitisinone mediated inhibition of CYP450 enzyme. Metabolism inborn error [5C50] [83]
Ubrogepant DM749I3 Moderate Decreased metabolism of Diltiazem caused by Ubrogepant mediated inhibition of CYP450 enzyme. Migraine [8A80] [183]
Propranolol DM79NTF Major Increased risk of cardiac depression by the combination of Diltiazem and Propranolol. Migraine [8A80] [82]
Rimegepant DMHOAUG Moderate Decreased metabolism of Diltiazem caused by Rimegepant mediated inhibition of CYP450 enzyme. Migraine [8A80] [184]
Exjade DMHPRWG Moderate Increased metabolism of Diltiazem caused by Exjade mediated induction of CYP450 enzyme. Mineral absorption/transport disorder [5C64] [92]
Flibanserin DM70DTN Major Decreased metabolism of Diltiazem caused by Flibanserin mediated inhibition of CYP450 enzyme. Mood disorder [6A60-6E23] [185]
Midazolam DMXOELT Moderate Decreased metabolism of Diltiazem caused by Midazolam mediated inhibition of CYP450 enzyme. Mood/affect symptom [MB24] [167]
Panobinostat DM58WKG Moderate Decreased metabolism of Diltiazem caused by Panobinostat mediated inhibition of CYP450 enzyme. Multiple myeloma [2A83] [186]
Thalidomide DM70BU5 Moderate Increased risk of ventricular arrhythmias by the combination of Diltiazem and Thalidomide. Multiple myeloma [2A83] [111]
Siponimod DM2R86O Major Increased risk of atrioventricular block by the combination of Diltiazem and Siponimod. Multiple sclerosis [8A40] [111]
Fingolimod DM5JVAN Major Increased risk of atrioventricular block by the combination of Diltiazem and Fingolimod. Multiple sclerosis [8A40] [187]
Ozanimod DMT6AM2 Moderate Increased risk of atrioventricular block by the combination of Diltiazem and Ozanimod. Multiple sclerosis [8A40] [188]
Deflazacort DMV0RNS Major Decreased metabolism of Diltiazem caused by Deflazacort mediated inhibition of CYP450 enzyme. Muscular dystrophy [8C70] [91]
Rifabutin DM1YBHK Major Increased metabolism of Diltiazem caused by Rifabutin mediated induction of CYP450 enzyme. Mycobacterium infection [1B10-1B21] [148]
Romidepsin DMT5GNL Moderate Decreased clearance of Diltiazem due to the transporter inhibition by Romidepsin. Mycosis fungoides [2B01] [189]
Fedratinib DM4ZBK6 Minor Decreased metabolism of Diltiazem caused by Fedratinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [91]
Nilotinib DM7HXWT Moderate Decreased clearance of Diltiazem due to the transporter inhibition by Nilotinib. Myeloproliferative neoplasm [2A20] [190]
Ruxolitinib DM7Q98D Minor Decreased metabolism of Diltiazem caused by Ruxolitinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [91]
Imatinib DM7RJXL Moderate Decreased metabolism of Diltiazem caused by Imatinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [191]
Dasatinib DMJV2EK Moderate Decreased metabolism of Diltiazem caused by Dasatinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [192]
Modafinil DMYILBE Moderate Increased metabolism of Diltiazem caused by Modafinil mediated induction of CYP450 enzyme. Narcolepsy [7A20] [92]
Prochlorperazine DM53SRA Moderate Additive hypotensive effects by the combination of Diltiazem and Prochlorperazine. Nausea/vomiting [MD90] [95]
Promethazine DM6I5GR Moderate Additive hypotensive effects by the combination of Diltiazem and Promethazine. Nausea/vomiting [MD90] [95]
Granisetron DMIUW25 Moderate Decreased metabolism of Diltiazem caused by Granisetron mediated inhibition of CYP450 enzyme. Nausea/vomiting [MD90] [84]
Thiethylperazine DMU3IET Moderate Additive hypotensive effects by the combination of Diltiazem and Thiethylperazine. Nausea/vomiting [MD90] [95]
Entrectinib DMMPTLH Major Decreased metabolism of Diltiazem caused by Entrectinib mediated inhibition of CYP450 enzyme. Non-small cell lung cancer [2C25] [111]
Sibutramine DMFJTDI Minor Decreased metabolism of Diltiazem caused by Sibutramine mediated inhibition of CYP450 enzyme. Obesity [5B80-5B81] [193]
Levomethadyl Acetate DM06HG5 Major Decreased metabolism of Diltiazem caused by Levomethadyl Acetate mediated inhibition of CYP450 enzyme. Opioid use disorder [6C43] [194]
S-297995 DM26IH8 Moderate Decreased metabolism of Diltiazem caused by S-297995 mediated inhibition of CYP450 enzyme. Opioid use disorder [6C43] [91]
Valdecoxib DMAY7H4 Moderate Decreased metabolism of Diltiazem caused by Valdecoxib mediated inhibition of CYP450 enzyme. Osteoarthritis [FA00-FA05] [195]
Olaparib DM8QB1D Major Decreased metabolism of Diltiazem caused by Olaparib mediated inhibition of CYP450 enzyme. Ovarian cancer [2C73] [111]
Rucaparib DM9PVX8 Moderate Decreased metabolism of Diltiazem caused by Rucaparib mediated inhibition of CYP450 enzyme. Ovarian cancer [2C73] [196]
MK-4827 DMLYGH4 Moderate Decreased clearance of Diltiazem due to the transporter inhibition by MK-4827. Ovarian cancer [2C73] [197]
Butorphanol DM5KYPJ Major Decreased metabolism of Diltiazem caused by Butorphanol mediated inhibition of CYP450 enzyme. Pain [MG30-MG3Z] [198]
Buprenorphine DMPRI8G Moderate Decreased metabolism of Diltiazem caused by Buprenorphine mediated inhibition of CYP450 enzyme. Pain [MG30-MG3Z] [199]
Hydrocodone DMQ2JO5 Major Decreased metabolism of Diltiazem caused by Hydrocodone mediated inhibition of CYP450 enzyme. Pain [MG30-MG3Z] [200]
Oxycodone DMXLKHV Major Decreased metabolism of Diltiazem caused by Oxycodone mediated inhibition of CYP450 enzyme. Pain [MG30-MG3Z] [111]
Albendazole DMYZ57N Moderate Decreased metabolism of Diltiazem caused by Albendazole mediated inhibition of CYP450 enzyme. Parasitic worm infestation [1F90] [84]
Rasagiline DM3WKQ4 Moderate Additive hypotensive effects by the combination of Diltiazem and Rasagiline. Parkinsonism [8A00] [126]
Pimavanserin DMR7IVC Moderate Decreased metabolism of Diltiazem caused by Pimavanserin mediated inhibition of CYP450 enzyme. Parkinsonism [8A00] [201]
Bromocriptine DMVE3TK Moderate Decreased metabolism of Diltiazem caused by Bromocriptine mediated inhibition of CYP450 enzyme. Parkinsonism [8A00] [84]
Abametapir DM2RX0I Moderate Decreased metabolism of Diltiazem caused by Abametapir mediated inhibition of CYP450 enzyme. Pediculosis [1G00] [202]
Lefamulin DME6G97 Major Decreased metabolism of Diltiazem caused by Lefamulin mediated inhibition of CYP450 enzyme. Pneumonia [CA40] [203]
Ergonovine DM0VEC1 Moderate Decreased metabolism of Diltiazem caused by Ergonovine mediated inhibition of CYP450 enzyme. Postpartum haemorrhage [JA43] [85]
Lonafarnib DMGM2Z6 Major Decreased metabolism of Diltiazem caused by Lonafarnib mediated inhibition of CYP450 enzyme. Premature ageing appearance [LD2B] [204]
Progesterone DMUY35B Moderate Decreased metabolism of Diltiazem caused by Progesterone mediated inhibition of CYP450 enzyme. Preterm labour/delivery [JB00] [84]
Enzalutamide DMGL19D Moderate Decreased metabolism of Diltiazem caused by Enzalutamide mediated inhibition of CYP450 enzyme. Prostate cancer [2C82] [205]
Relugolix DMK7IWL Major Decreased clearance of Diltiazem due to the transporter inhibition by Relugolix. Prostate cancer [2C82] [206]
Tamsulosin DM5QF9V Moderate Decreased metabolism of Diltiazem caused by Tamsulosin mediated inhibition of CYP450 enzyme. Prostate hyperplasia [GA90] [207]
Silodosin DMJSBT6 Moderate Decreased clearance of Diltiazem due to the transporter inhibition by Silodosin. Prostate hyperplasia [GA90] [208]
Dutasteride DMQ4TJK Moderate Decreased metabolism of Diltiazem caused by Dutasteride mediated inhibition of CYP450 enzyme. Prostate hyperplasia [GA90] [209]
Finasteride DMWV3TZ Moderate Decreased metabolism of Diltiazem caused by Finasteride mediated inhibition of CYP450 enzyme. Prostate hyperplasia [GA90] [84]
Levomepromazine DMIKFEL Moderate Additive hypotensive effects by the combination of Diltiazem and Levomepromazine. Psychotic disorder [6A20-6A25] [95]
Fluphenazine DMIT8LX Moderate Additive hypotensive effects by the combination of Diltiazem and Fluphenazine. Psychotic disorder [6A20-6A25] [95]
Bosentan DMIOGBU Moderate Increased metabolism of Diltiazem caused by Bosentan mediated induction of CYP450 enzyme. Pulmonary hypertension [BB01] [92]
Riociguat DMXBLMP Moderate Decreased metabolism of Diltiazem caused by Riociguat mediated inhibition of CYP450 enzyme. Pulmonary hypertension [BB01] [111]
Everolimus DM8X2EH Major Decreased clearance of Diltiazem due to the transporter inhibition by Everolimus. Renal cell carcinoma [2C90] [210]
Axitinib DMGVH6N Moderate Decreased metabolism of Diltiazem caused by Axitinib mediated inhibition of CYP450 enzyme. Renal cell carcinoma [2C90] [91]
Temsirolimus DMS104F Moderate Decreased metabolism of Diltiazem caused by Temsirolimus mediated inhibition of CYP450 enzyme. Renal cell carcinoma [2C90] [211]
Upadacitinib DM32B5U Moderate Decreased metabolism of Diltiazem caused by Upadacitinib mediated inhibition of CYP450 enzyme. Rheumatoid arthritis [FA20] [212]
Tofacitinib DMBS370 Moderate Decreased metabolism of Diltiazem caused by Tofacitinib mediated inhibition of CYP450 enzyme. Rheumatoid arthritis [FA20] [111]
Nafcillin DMN9RPO Moderate Increased metabolism of Diltiazem caused by Nafcillin mediated induction of CYP450 enzyme. Rheumatoid arthritis [FA20] [213]
Quetiapine DM1N62C Moderate Decreased metabolism of Diltiazem caused by Quetiapine mediated inhibition of CYP450 enzyme. Schizophrenia [6A20] [214]
Mesoridazine DM2ZGAN Moderate Additive hypotensive effects by the combination of Diltiazem and Mesoridazine. Schizophrenia [6A20] [95]
Thioridazine DM35M8J Moderate Additive hypotensive effects by the combination of Diltiazem and Thioridazine. Schizophrenia [6A20] [95]
Aripiprazole DM3NUMH Moderate Additive hypotensive effects by the combination of Diltiazem and Aripiprazole. Schizophrenia [6A20] [95]
Iloperidone DM6AUFY Moderate Additive hypotensive effects by the combination of Diltiazem and Iloperidone. Schizophrenia [6A20] [95]
Paliperidone DM7NPJS Moderate Additive hypotensive effects by the combination of Diltiazem and Paliperidone. Schizophrenia [6A20] [95]
Loxapine DM8AI9U Moderate Additive hypotensive effects by the combination of Diltiazem and Loxapine. Schizophrenia [6A20] [95]
Haloperidol DM96SE0 Moderate Additive hypotensive effects by the combination of Diltiazem and Haloperidol. Schizophrenia [6A20] [95]
Perphenazine DMA4MRX Moderate Additive hypotensive effects by the combination of Diltiazem and Perphenazine. Schizophrenia [6A20] [95]
Molindone DMAH70G Moderate Additive hypotensive effects by the combination of Diltiazem and Molindone. Schizophrenia [6A20] [95]
Chlorpromazine DMBGZI3 Moderate Additive hypotensive effects by the combination of Diltiazem and Chlorpromazine. Schizophrenia [6A20] [95]
Thiothixene DMDINC4 Moderate Additive hypotensive effects by the combination of Diltiazem and Thiothixene. Schizophrenia [6A20] [95]
Clozapine DMFC71L Moderate Additive hypotensive effects by the combination of Diltiazem and Clozapine. Schizophrenia [6A20] [95]
Trifluoperazine DMKBYWI Moderate Additive hypotensive effects by the combination of Diltiazem and Trifluoperazine. Schizophrenia [6A20] [95]
Risperidone DMN6DXL Moderate Additive hypotensive effects by the combination of Diltiazem and Risperidone. Schizophrenia [6A20] [95]
Amisulpride DMSJVAM Moderate Increased risk of ventricular arrhythmias by the combination of Diltiazem and Amisulpride. Schizophrenia [6A20] [91]
Asenapine DMSQZE2 Moderate Additive hypotensive effects by the combination of Diltiazem and Asenapine. Schizophrenia [6A20] [95]
Pimozide DMW83TP Major Decreased metabolism of Diltiazem caused by Pimozide mediated inhibition of CYP450 enzyme. Schizophrenia [6A20] [111]
Fentanyl DM8WAHT Major Decreased metabolism of Diltiazem caused by Fentanyl mediated inhibition of CYP450 enzyme. Sensation disturbance [MB40] [111]
Avanafil DM75CXN Major Decreased metabolism of Diltiazem caused by Avanafil mediated inhibition of CYP450 enzyme. Sexual dysfunction [HA00-HA01] [215]
Tadalafil DMJZHT1 Moderate Decreased metabolism of Diltiazem caused by Tadalafil mediated inhibition of CYP450 enzyme. Sexual dysfunction [HA00-HA01] [216]
Voxelotor DMCS6M5 Moderate Decreased metabolism of Diltiazem caused by Voxelotor mediated inhibition of CYP450 enzyme. Sickle-cell disorder [3A51] [217]
LDE225 DMM9F25 Major Decreased metabolism of Diltiazem caused by LDE225 mediated inhibition of CYP450 enzyme. Skin cancer [2C30-2C37] [218]
Telotristat ethyl DMDIYFZ Moderate Increased metabolism of Diltiazem caused by Telotristat ethyl mediated induction of CYP450 enzyme. Small intestine developmental anomaly [DA90] [91]
Larotrectinib DM26CQR Moderate Decreased metabolism of Diltiazem caused by Larotrectinib mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [111]
Cyclophosphamide DM4O2Z7 Moderate Decreased metabolism of Diltiazem caused by Cyclophosphamide mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [84]
Vinblastine DM5TVS3 Moderate Decreased metabolism of Diltiazem caused by Vinblastine mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [84]
Docetaxel DMDI269 Major Decreased clearance of Diltiazem due to the transporter inhibition by Docetaxel. Solid tumour/cancer [2A00-2F9Z] [219]
Trabectedin DMG3Y89 Moderate Decreased metabolism of Diltiazem caused by Trabectedin mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [91]
Armodafinil DMGB035 Moderate Increased metabolism of Diltiazem caused by Armodafinil mediated induction of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [92]
LEE011 DMMX75K Moderate Decreased metabolism of Diltiazem caused by LEE011 mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [111]
Etoposide DMNH3PG Moderate Decreased metabolism of Diltiazem caused by Etoposide mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [84]
Norethindrone DMTY169 Moderate Decreased metabolism of Diltiazem caused by Norethindrone mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [119]
Taxol DMUOT9V Moderate Decreased metabolism of Diltiazem caused by Taxol mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [220]
Doxorubicin DMVP5YE Moderate Decreased metabolism of Diltiazem caused by Doxorubicin mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [119]
Vinorelbine DMVXFYE Moderate Decreased metabolism of Diltiazem caused by Vinorelbine mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [84]
Pomalidomide DMTGBAX Moderate Decreased metabolism of Diltiazem caused by Pomalidomide mediated inhibition of CYP450 enzyme. Systemic sclerosis [4A42] [111]
Fostamatinib DM6AUHV Moderate Decreased metabolism of Diltiazem caused by Fostamatinib mediated inhibition of CYP450 enzyme. Thrombocytopenia [3B64] [221]
Lusutrombopag DMH6IKO Moderate Decreased clearance of Diltiazem due to the transporter inhibition by Lusutrombopag. Thrombocytopenia [3B64] [196]
Apixaban DM89JLN Moderate Decreased clearance of Diltiazem due to the transporter inhibition by Apixaban. Thrombosis [DB61-GB90] [91]
Brilinta DMBR01X Moderate Decreased metabolism of Diltiazem caused by Brilinta mediated inhibition of CYP450 enzyme. Thrombosis [DB61-GB90] [91]
Cabozantinib DMIYDT4 Moderate Decreased metabolism of Diltiazem caused by Cabozantinib mediated inhibition of CYP450 enzyme. Thyroid cancer [2D10] [222]
Sirolimus DMGW1ID Moderate Decreased metabolism of Diltiazem caused by Sirolimus mediated inhibition of CYP450 enzyme. Transplant rejection [NE84] [223]
Tacrolimus DMZ7XNQ Moderate Decreased metabolism of Diltiazem caused by Tacrolimus mediated inhibition of CYP450 enzyme. Transplant rejection [NE84] [223]
Saxagliptin DMGXENV Moderate Decreased metabolism of Diltiazem caused by Saxagliptin mediated inhibition of CYP450 enzyme. Type 2 diabetes mellitus [5A11] [91]
Elagolix DMB2C0E Moderate Decreased clearance of Diltiazem due to the transporter inhibition by Elagolix. Uterine fibroid [2E86] [224]
Astemizole DM2HN6Q Moderate Decreased metabolism of Diltiazem caused by Astemizole mediated inhibition of CYP450 enzyme. Vasomotor/allergic rhinitis [CA08] [84]
Methdilazine DMAUHQX Moderate Additive hypotensive effects by the combination of Diltiazem and Methdilazine. Vasomotor/allergic rhinitis [CA08] [95]
Trimeprazine DMEMV9D Moderate Additive hypotensive effects by the combination of Diltiazem and Trimeprazine. Vasomotor/allergic rhinitis [CA08] [225]
Fluticasone DMGCSVF Moderate Decreased metabolism of Diltiazem caused by Fluticasone mediated inhibition of CYP450 enzyme. Vasomotor/allergic rhinitis [CA08] [111]
Propafenone DMPIBJK Moderate Decreased metabolism of Diltiazem caused by Propafenone mediated inhibition of CYP450 enzyme. Ventricular tachyarrhythmia [BC71] [226]
Amiodarone DMUTEX3 Major Increased risk of bradycardia by the combination of Diltiazem and Amiodarone. Ventricular tachyarrhythmia [BC71] [227]
⏷ Show the Full List of 300 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG
DIG Name DIG ID PubChem CID Functional Classification
Allura red AC dye E00338 33258 Colorant
D&C red no. 28 E00491 6097185 Colorant
Dibutyl phthalate E00064 3026 Plasticizing agent; Solvent
Diethyl phthalate E00135 6781 Plasticizing agent; Solvent
Ethyl acrylate E00191 8821 Film/membrane-forming agent; Flavoring agent
FD&C blue no. 1 E00263 19700 Colorant
FD&C blue no. 2 E00446 2723854 Colorant
Fumaric acid E00420 444972 Acidulant; Antioxidant; Complexing agent; Flavoring agent; Solubilizing agent
Mannitol E00103 6251 Diluent; Flavoring agent; Lyophilization aid; Plasticizing agent; Tonicity agent
methylparaben E00149 7456 Antimicrobial preservative
Oleic acid E00421 445639 Emulsifying agent; Penetration agent; Solubilizing agent
Phenoxyisopropanol E00386 92839 Antimicrobial preservative
Quinoline yellow WS E00309 24671 Colorant
Sodium lauryl sulfate E00464 3423265 Emulsifying agent; Modified-release agent; Penetration agent; Solubilizing agent; Surfactant; lubricant
Stearic acid E00079 5281 Emulsifying agent; Solubilizing agent; Viscosity-controlling agent; lubricant
Sucrose stearate E00502 9898327 Dispersing agent; Emulsifying agent; Modified-release agent; Solubilizing agent; Surfactant; lubricant
Sunset yellow FCF E00255 17730 Colorant
Acetyltributyl citrate E00127 6505 Plasticizing agent
Acetyltriethyl citrate E00126 6504 Plasticizing agent
Allyl sucrose E00604 129637651 Other agent
Ammonia E00007 222 Alkalizing agent
Beta-D-lactose E00099 6134 Diluent; Dry powder inhaler carrier; Lyophilization aid
Carboxymethylcellulose sodium E00621 Not Available Adsorbent; Binding agent; Disintegrant; Emulsifying agent; Suspending agent; Viscosity-controlling agent
Carmellose sodium E00625 Not Available Disintegrant
Dextrin E00359 62698 Binding agent; Diluent; Microencapsulating agent; Stiffening agent; Suspending agent; Viscosity-controlling agent
Dibutyl sebacate E00160 7986 Plasticizing agent
Eisenoxyd E00585 56841934 Colorant
FD&C red no. 3 E00629 Not Available Colorant
Ferric hydroxide oxide yellow E00539 23320441 Colorant
Ferrosoferric oxide E00231 14789 Colorant
Hypromellose E00634 Not Available Coating agent
Lactose monohydrate E00393 104938 Binding agent; Diluent; Dry powder inhaler carrier; Lyophilization aid
Magnesium stearate E00208 11177 lubricant
Polysorbate 80 E00665 Not Available Dispersing agent; Emollient; Emulsifying agent; Plasticizing agent; Solubilizing agent; Surfactant; Suspending agent
Potassium hydroxide E00233 14797 Alkalizing agent
Povidone E00667 Not Available Binding agent; Coating agent; Disintegrant; Film/membrane-forming agent; Solubilizing agent; Suspending agent
Propylene glycol E00040 1030 Antimicrobial preservative; Humectant; Plasticizing agent; Solvent
Saccharose E00091 5988 Binding agent; Coating agent; Cryoprotectant; Diluent; Flavoring agent; Suspending agent; Viscosity-controlling agent
Silicon dioxide E00670 Not Available Anticaking agent; Opacifying agent; Viscosity-controlling agent
Talc E00520 16211421 Anticaking agent; Diluent; Glidant; lubricant
Titanium dioxide E00322 26042 Coating agent; Colorant; Opacifying agent
Triacetin E00080 5541 Humectant; Plasticizing agent; Solvent
Triethyl citrate E00128 6506 Plasticizing agent; Solvent
Vinylpyrrolidone E00668 Not Available Binding agent; Coating agent; Disintegrant; Film/membrane-forming agent; Solubilizing agent; Suspending agent
⏷ Show the Full List of 44 Pharmaceutical Excipients of This Drug
Pharmaceutical Formulation
Formulation Name Drug Dosage Dosage Form Route
Diltiazem 120 mg capsule 120 mg 24 HR Extended Release Oral Capsule Oral
Diltiazem 120 mg capsule 120 mg 12 HR Extended Release Oral Capsule Oral
Diltiazem 60 mg capsule 60 mg 12 HR Extended Release Oral Capsule Oral
Diltiazem 90 mg capsule 90 mg 12 HR Extended Release Oral Capsule Oral
Diltiazem 120 mg capsule 120 mg 24 HR Extended Release Capsule Oral
Diltiazem 180 mg capsule 180 mg 24 HR Extended Release Capsule Oral
Diltiazem 240 mg capsule 240 mg 24 HR Extended Release Capsule Oral
Diltiazem 300 mg capsule 300 mg 24 HR Extended Release Capsule Oral
Diltiazem 360 mg capsule 360 mg 24 HR Extended Release Capsule Oral
Diltiazem 420 mg capsule 420 mg 24 HR Extended Release Capsule Oral
Diltiazem 180 mg capsule 180 mg 24 HR Extended Release Oral Capsule Oral
Diltiazem 120 mg tablet 120 mg 24 HR Extended Release Oral Tablet Oral
Diltiazem 120 mg tablet 120 mg Oral Tablet Oral
Diltiazem 30 mg tablet 30 mg Oral Tablet Oral
Diltiazem 60 mg tablet 60 mg Oral Tablet Oral
Diltiazem 90 mg tablet 90 mg Oral Tablet Oral
Diltiazem 240 mg capsule 240 mg 24 HR Extended Release Oral Capsule Oral
Diltiazem 420 mg capsule 420 mg 24 HR Extended Release Oral Capsule Oral
Diltiazem 300 mg capsule 300 mg 24 HR Extended Release Oral Capsule Oral
Diltiazem 240 mg tablet 240 mg 24 HR Extended Release Oral Tablet Oral
Diltiazem 360 mg tablet 360 mg 24 HR Extended Release Oral Tablet Oral
Diltiazem 420 mg tablet 420 mg 24 HR Extended Release Oral Tablet Oral
Diltiazem 180 mg tablet 180 mg 24 HR Extended Release Oral Tablet Oral
Diltiazem 300 mg tablet 300 mg 24 HR Extended Release Oral Tablet Oral
Diltiazem 360 mg capsule 360 mg 24 HR Extended Release Oral Capsule Oral
Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2298).
2 Partial restoration of mutant enzyme homeostasis in three distinct lysosomal storage disease cell lines by altering calcium homeostasis. PLoS Biol. 2008 Feb;6(2):e26.
3 BDDCS applied to over 900 drugs
4 CARDIZEM? LA (diltiazem hydrochloride) extended-release tablets - FDA Label
5 Diltiazem Hydrochloride Injection Label - Bedford Laboratories
6 Authors unspecified: Doxepin .
7 Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
8 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
9 Egr-1, the potential target of calcium channel blockers in cardioprotection with ischemia/reperfusion injury in rats. Cell Physiol Biochem. 2009;24(1-2):17-24.
10 Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
11 Comparative metabolic capabilities of CYP3A4, CYP3A5, and CYP3A7. Drug Metab Dispos. 2002 Aug;30(8):883-91.
12 Drug interactions with calcium channel blockers: possible involvement of metabolite-intermediate complexation with CYP3A. Drug Metab Dispos. 2000 Feb;28(2):125-30.
13 Effects of CYP3A4 inhibition by diltiazem on pharmacokinetics and dynamics of diazepam in relation to CYP2C19 genotype status. Drug Metab Dispos. 2001 Oct;29(10):1284-9.
14 Significant impacts of CYP3A4*1G and CYP3A5*3 genetic polymorphisms on the pharmacokinetics of diltiazem and its main metabolites in Chinese adult kidney transplant patients. J Clin Pharm Ther. 2016 Jun;41(3):341-7.
15 Role of CYP3A4 in human hepatic diltiazem N-demethylation: inhibition of CYP3A4 activity by oxidized diltiazem metabolites. J Pharmacol Exp Ther. 1997 Jul;282(1):294-300.
16 FDA Drug Development and Drug Interactions
17 Expression levels and activation of a PXR variant are directly related to drug resistance in osteosarcoma cell lines. Cancer. 2007 Mar 1;109(5):957-65.
18 Contribution of human hepatic cytochrome P450 isoforms to regioselective hydroxylation of steroid hormones. Xenobiotica. 1998 Jun;28(6):539-47.
19 Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther. 2004 Sep;310(3):1062-75.
20 Isoform-specific regulation of cytochromes P450 expression by estradiol and progesterone. Drug Metab Dispos. 2013 Feb;41(2):263-9.
21 Metabolic interactions between acetaminophen (paracetamol) and two flavonoids, luteolin and quercetin, through in-vitro inhibition studies. J Pharm Pharmacol. 2017 Dec;69(12):1762-1772.
22 Potent mechanism-based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates. Br J Pharmacol. 2012 Apr;165(8):2787-98.
23 Effects of morin on the pharmacokinetics of etoposide in rats. Biopharm Drug Dispos. 2007 Apr;28(3):151-6.
24 The metabolism of zidovudine by human liver microsomes in vitro: formation of 3'-amino-3'-deoxythymidine. Biochem Pharmacol. 1994 Jul 19;48(2):267-76.
25 Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
26 Inhibitory effects of anticancer drugs on dextromethorphan-O-demethylase activity in human liver microsomes. Cancer Chemother Pharmacol. 1993;32(6):491-5.
27 Effect of genetic polymorphism on the metabolism of endogenous neuroactive substances, progesterone and p-tyramine, catalyzed by CYP2D6. Brain Res Mol Brain Res. 2004 Oct 22;129(1-2):117-23.
28 CYP2D6 polymorphisms and tamoxifen metabolism: clinical relevance. Curr Oncol Rep. 2010 Jan;12(1):7-15.
29 Inhibition of cytochrome P450 2D6: structure-activity studies using a series of quinidine and quinine analogues. Chem Res Toxicol. 2003 Apr;16(4):450-9.
30 Effects of propofol on human hepatic microsomal cytochrome P450 activities. Xenobiotica. 1998 Sep;28(9):845-53.
31 Pharmacogenetics of schizophrenia. Am J Med Genet. 2000 Spring;97(1):98-106.
32 Roles of CYP2A6 and CYP2B6 in nicotine C-oxidation by human liver microsomes. Arch Toxicol. 1999 Mar;73(2):65-70.
33 Structure-activity relationship for human cytochrome P450 substrates and inhibitors. Drug Metab Rev. 2002 Feb-May;34(1-2):69-82.
34 Drug related genetic polymorphisms affecting adverse reactions to methotrexate, vinblastine, doxorubicin and cisplatin in patients with urothelial cancer. J Urol. 2008 Dec;180(6):2389-95.
35 Human prostate CYP3A5: identification of a unique 5'-untranslated sequence and characterization of purified recombinant protein. Biochem Biophys Res Commun. 1999 Jul 14;260(3):676-81.
36 Polymorphisms in cytochrome P4503A5 (CYP3A5) may be associated with race and tumor characteristics, but not metabolism and side effects of tamoxifen in breast cancer patients. Cancer Lett. 2005 Jan 10;217(1):61-72.
37 Drug Interactions Flockhart Table
38 Induction of hepatic CYP2E1 by a subtoxic dose of acetaminophen in rats: increase in dichloromethane metabolism and carboxyhemoglobin elevation. Drug Metab Dispos. 2007 Oct;35(10):1754-8.
39 Urinary 6 beta-hydroxycortisol excretion in rheumatoid arthritis. Br J Rheumatol. 1997 Jan;36(1):54-8.
40 Clinical pharmacokinetics of imatinib. Clin Pharmacokinet. 2005;44(9):879-94.
41 Kinetics and regulation of cytochrome P450-mediated etoposide metabolism. Drug Metab Dispos. 2004 Sep;32(9):993-1000.
42 Differential mechanism-based inhibition of CYP3A4 and CYP3A5 by verapamil. Drug Metab Dispos. 2005 May;33(5):664-71.
43 The role of cytochrome P450 3A (CYP3A) isoform(s) in oxidative metabolism of testosterone and benzphetamine in human adult and fetal liver. J Steroid Biochem Mol Biol. 1993 Jan;44(1):61-7.
44 Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
45 Prediction of cytochrome P450 3A inhibition by verapamil enantiomers and their metabolites. Drug Metab Dispos. 2004 Feb;32(2):259-66.
46 The role of human cytochrome P450 enzymes in the formation of 2-hydroxymetronidazole: CYP2A6 is the high affinity (low Km) catalyst. Drug Metab Dispos. 2013 Sep;41(9):1686-94.
47 Roles of cytochromes P450 1A2, 2A6, and 2C8 in 5-fluorouracil formation from tegafur, an anticancer prodrug, in human liver microsomes. Drug Metab Dispos. 2000 Dec;28(12):1457-63.
48 Role of cytochrome P450 2C8 in drug metabolism and interactions. Pharmacol Rev. 2016 Jan;68(1):168-241.
49 Differential expression and function of CYP2C isoforms in human intestine and liver. Pharmacogenetics. 2003 Sep;13(9):565-75.
50 Analysis of human cytochrome P450 2C8 substrate specificity using a substrate pharmacophore and site-directed mutants. Biochemistry. 2004 Dec 14;43(49):15379-92.
51 Interaction of sorafenib and cytochrome P450 isoenzymes in patients with advanced melanoma: a phase I/II pharmacokinetic interaction study. Cancer Chemother Pharmacol. 2011 Nov;68(5):1111-8.
52 PharmGKB summary: mycophenolic acid pathway. Pharmacogenet Genomics. 2014 Jan;24(1):73-9.
53 Possible involvement of multiple human cytochrome P450 isoforms in the liver metabolism of propofol. Br J Anaesth. 1998 Jun;80(6):788-95.
54 Progesterone and testosterone hydroxylation by cytochromes P450 2C19, 2C9, and 3A4 in human liver microsomes. Arch Biochem Biophys. 1997 Oct 1;346(1):161-9.
55 Tamoxifen inhibits cytochrome P450 2C9 activity in breast cancer patients. J Chemother. 2006 Aug;18(4):421-4.
56 Characterization of the oxidative metabolites of 17beta-estradiol and estrone formed by 15 selectively expressed human cytochrome p450 isoforms. Endocrinology. 2003 Aug;144(8):3382-98.
57 Drug-drug interactions with imatinib: an observational study. Medicine (Baltimore). 2016 Oct;95(40):e5076.
58 New insights into the structural features and functional relevance of human cytochrome P450 2C9. Part I. Curr Drug Metab. 2009 Dec;10(10):1075-126.
59 A potential role for the estrogen-metabolizing cytochrome P450 enzymes in human breast carcinogenesis. Breast Cancer Res Treat. 2003 Dec;82(3):191-7.
60 A mechanistic approach to antiepileptic drug interactions. Ann Pharmacother. 1998 May;32(5):554-63.
61 High-dose rabeprazole/amoxicillin therapy as the second-line regimen after failure to eradicate H. pylori by triple therapy with the usual doses of a proton pump inhibitor, clarithromycin and amoxicillin. Hepatogastroenterology. 2003 Nov-Dec;50(54):2274-8.
62 Cytochrome P450 pharmacogenetics and cancer. Oncogene. 2006 Mar 13;25(11):1679-91.
63 CYP2C19*17 is associated with decreased breast cancer risk. Breast Cancer Res Treat. 2009 May;115(2):391-6.
64 Cytochromes of the P450 2C subfamily are the major enzymes involved in the O-demethylation of verapamil in humans. Naunyn Schmiedebergs Arch Pharmacol. 1995 Dec;353(1):116-21.
65 Diclofenac and its derivatives as tools for studying human cytochromes P450 active sites: particular efficiency and regioselectivity of P450 2Cs. Biochemistry. 1999 Oct 26;38(43):14264-70.
66 Organic anion-transporting polypeptide B (OATP-B) and its functional comparison with three other OATPs of human liver. Gastroenterology. 2001 Feb;120(2):525-33.
67 Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
68 MDR1 (ABCB1) G1199A (Ser400Asn) polymorphism alters transepithelial permeability and sensitivity to anticancer agents. Cancer Chemother Pharmacol. 2009 Jun;64(1):183-8.
69 Folate transporter expression decreases in the human placenta throughout pregnancy and in pre-eclampsia. Pregnancy Hypertens. 2012 Apr;2(2):123-31.
70 Comparative studies on in vitro methods for evaluating in vivo function of MDR1 P-glycoprotein. Pharm Res. 2001 Dec;18(12):1660-8.
71 Antiestrogens and steroid hormones: substrates of the human P-glycoprotein. Biochem Pharmacol. 1994 Jul 19;48(2):287-92.
72 Association of genetic polymorphisms in the influx transporter SLCO1B3 and the efflux transporter ABCB1 with imatinib pharmacokinetics in patients with chronic myeloid leukemia. Ther Drug Monit. 2011 Apr;33(2):244-50.
73 Sulfobutyl ether-alkyl ether mixed cyclodextrin derivatives with enhanced inclusion ability. J Pharm Sci. 2009 Dec;98(12):4769-80.
74 Treatment of essential hypertension with calcium channel blockers: what is the place of lercanidipine Expert Opin Drug Metab Toxicol. 2009 Aug;5(8):981-7.
75 Pregabalin reduces the release of synaptic vesicles from cultured hippocampal neurons. Mol Pharmacol. 2006 Aug;70(2):467-76.
76 A first drug combination for the treatment of arterial hypertension with a calcium channel antagonist (amlodipine besylate) and an angiotensin receptor blocker (valsartan): Exforge. Rev Med Liege. 2007 Nov;62(11):688-94.
77 Efficacy and safety of mirogabalin (DS-5565) for the treatment of diabetic peripheral neuropathic pain: a randomized, double-blind, placebo- and active comparator-controlled, adaptive proof-of-concept phase 2 study. Diabetes Care. 2014 Dec;37(12):3253-61.
78 Methodology for rapid measures of glutamate release in rat brain slices using ceramic-based microelectrode arrays: basic characterization and drug pharmacology. Brain Res. 2011 Jul 15;1401:1-9.
79 Scaffold-based design and synthesis of potent N-type calcium channel blockers. Bioorg Med Chem Lett. 2009 Nov 15;19(22):6467-72.
80 Enantioselective synthesis of PD144723: a potent stereospecific anticonvulsant, Bioorg. Med. Chem. Lett. 4(6):823-826 (1994).
81 Structure-activity relationships of alpha-amino acid ligands for the alpha2delta subunit of voltage-gated calcium channels. Bioorg Med Chem Lett. 2006 Mar 1;16(5):1138-41.
82 Anastassiades CJ "Nifedipine and beta-blocker drugs." Br Med J 281 (1980): 1251-2. [PMID: 6107167]
83 Canadian Pharmacists Association.
84 Abernethy DR, Egan JM, Dickinson TH, Carrum G "Substrate-selective inhibition by verapamil and diltiazem: differential disposition of antipyrine and theophylline in humans." J Pharmacol Exp Ther 244 (1988): 994-9. [PMID: 3252045]
85 Francis H, Tyndall A, Webb J "Severe vascular spasm due to erythromycin-ergotamine interaction." Clin Rheumatol 3 (1984): 243-6. [PMID: 6236021]
86 Bidstrup TB, Bjornsdottir I, Sidelmann UG, Thomsen MS, Hansen KT "CYP2C8 and CYP3A4 are the principal enzymes involved in the human in vitro biotransformation of the insulin secretagogue repaglinide." Br J Clin Pharmacol 56 (2003): 305-14. [PMID: 12919179]
87 Product Information. Actos (pioglitazone) Takeda Pharmaceuticals America, Lincolnshire, IL.
88 Product Information. Tibsovo (ivosidenib). Agios Pharmaceuticals, Cambridge, MA.
89 Dutreix C, Munarini F, Lorenzo S, Roesel J, Wang Y "Investigation into CYP3A4-mediated drug-drug interactions on midostaurin in healthy volunteers." Cancer Chemother Pharmacol 72 (2013): 1223-34. [PMID: 24085261]
90 Multum Information Services, Inc. Expert Review Panel.
91 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
92 Borcherding SM, Baciewicz AM, Self TH "Update on rifampin drug interactions." Arch Intern Med 152 (1992): 711-6. [PMID: 1558427]
93 Lamberg TS, Kivisto KT, Neuvonen PJ "Effects of verapamil and diltiazem on the pharmacokinetics and pharmacodynamics of buspirone." Clin Pharmacol Ther 63 (1998): 640-5. [PMID: 9663178]
94 Lledo P, Abrams SM, Johnston A, Patel M, Pearson RM, Turner P. Influence of debrisoquine hydroxylation phenotype on the pharmacokinetics of mexiletine. Eur J Clin Pharmacol. 1993;44(1):63-67. [PMID: 8436157]
95 Aronowitz JS, Chakos MH, Safferman AZ, Lieberman JA "Syncope associated with the combination of clozapine and enalapril." J Clin Psychopharmacol 14 (1994): 429-30. [PMID: 7884028]
96 Heinig R, Adelmann HG, Ahr G "The effect of ketoconazole on the pharmacokinetics, pharmacodynamics and safety of nisoldipine." Eur J Clin Pharmacol 55 (1999): 57-60. [PMID: 10206086]
97 Bolland MJ, Bagg W, Thomas MG, Lucas JA, Ticehurst R, Black PN "Cushing's syndrome due to interaction between inhaled corticosteroids and itraconazole." Ann Pharmacother 38 (2004): 46-9. [PMID: 14742792]
98 Product Information. Zylo Filmtab (zileuton). Abbott Pharmaceutical, Abbott Park, IL.
99 Product Information. Synercid (dalfopristin-quinupristin) Rhone-Poulenc Rorer, Collegeville, PA.
100 Product Information. Ketek (telithromycin). Aventis Pharmaceuticals, Bridgewater, NJ.
101 Product Information. Turalio (pexidartinib). Daiichi Sankyo, Inc., Parsippany, NJ.
102 Adachi Y, Suzuki H, Sugiyama Y "Quantitative evaluation of the function of small intestinal P-glycoprotein: comparative studies between in Situ and in Vivo." Pharm Res 20 (2003): 1163-9. [PMID: 12948013]
103 Product Information. Talzenna (talazoparib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
104 Product Information. Ixempra (ixabepilone). Bristol-Myers Squibb, Princeton, NJ.
105 Product Information. Tykerb (lapatinib). Novartis Pharmaceuticals, East Hanover, NJ.
106 Abbas R, Hug BA, Leister C, Burns J, Sonnichsen D "Pharmacokinetics of oral neratinib during co-administration of ketoconazole in healthy subjects." Br J Clin Pharmacol 71 (2011): 522-7. [PMID: 21395644]
107 Product Information. Verzenio (abemaciclib). Lilly, Eli and Company, Indianapolis, IN.
108 Product Information. Tukysa (tucatinib). Seattle Genetics Inc, Bothell, WA.
109 Product Information. Jevtana (cabazitaxel). sanofi-aventis , Bridgewater, NJ.
110 Product Information. Fareston (toremifene). Schering Laboratories, Kenilworth, NJ.
111 Cerner Multum, Inc. "Australian Product Information.".
112 Product Information. Raxar (grepafloxacin). Glaxo Wellcome, Research Triangle Park, NC.
113 Agbin NE, Brater DC, Hall SD "Interaction of diltiazem with lovastatin and pravastatin." Clin Pharmacol Ther 61 (1997): 201. [PMID: 9797793]
114 Product Information. Opsumit (macitentan). Actelion Pharmaceuticals US Inc, South San Francisco, CA.
115 Product Information. Daurismo (glasdegib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
116 Product Information. Arcapta Neohaler (indacaterol). Novartis Pharmaceuticals, East Hanover, NJ.
117 Product Information. Dificid (fidaxomicin). Optimer Pharmaceuticals, San Diego, CA.
118 Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7. [PMID: 3725002]
119 Renton KW "Inhibition of hepatic microsomal drug metabolism by the calcium channel blockers diltiazem and verapamil." Biochem Pharmacol 34 (1985): 2549-53. [PMID: 4015695]
120 Product Information. Korlym (mifepristone). Corcept Therapeutics Incorporated, Menlo Park, CA.
121 Product Information. Prevymis (letermovir). Merck & Company Inc, Whitehouse Station, NJ.
122 Product Information. Xarelto (rivaroxaban). Bayer Inc, Toronto, IA.
123 Product Information. Emend (aprepitant). Merck & Company Inc, West Point, PA.
124 Product Information. Viibryd (vilazodone). Trovis Pharmaceuticals LLC, New Haven, CT.
125 Product Information. Serzone (nefazodone). Bristol-Myers Squibb, Princeton, NJ.
126 Ban TA "Drug interactions with psychoactive drugs." Dis Nerv Syst 36 (1975): 164-6. [PMID: 1116424]
127 Product Information. Celexa (citalopram). Forest Pharmaceuticals, St. Louis, MO.
128 Product Information. Rexulti (brexpiprazole). Otsuka American Pharmaceuticals Inc, Rockville, MD.
129 Okubo M, Murayama N, Miura J, Chiba Y, Yamazaki H "Effects of cytochrome P450 2D6 and 3A5 genotypes and possible coadministered medicines on the metabolic clearance of antidepressant mirtazapine in Japanese patients." Biochem Pharmacol 93 (2015): 104-9. [PMID: 25475885]
130 Product Information. Polivy (polatuzumab vedotin). Genentech, South San Francisco, CA.
131 Nakasa H, Nakamura H, Ono S, Tsutsui M, Kiuchi M, Ohmori S, Kitada M "Prediction of drug-drug interactions of zonisamide metabolism in humans from in vitro data." Eur J Clin Pharmacol 54 (1998): 177-83. [PMID: 9626925]
132 Ahmad S "Nifedipine-phenytoin interaction." J Am Coll Cardiol 3 (1984): 1582. [PMID: 6425385]
133 Ahmad S "Diltiazem-carbamazepine interaction." Am Heart J 120 (1990): 1485-6. [PMID: 2248204]
134 Rubin AS, Zablocki AD "Hyperkalemia, verapamil, and dantrolene." Anesthesiology 66 (1987): 246-9. [PMID: 3813090]
135 Product Information. Aliqopa (copanlisib). Bayer Pharmaceutical Inc, West Haven, CT.
136 Product Information. Tazverik (tazemetostat). Epizyme, Inc, Cambridge, MA.
137 Product Information. VESIcare (solifenacin). GlaxoSmithKline, Research Triangle Park, NC.
138 Product Information. Myrbetriq (mirabegron). Astellas Pharma US, Inc, Deerfield, IL.
139 Brynne N, Forslund C, Hallen B, Gustafsson LL, Bertilsson L "Ketoconazole inhibits the metabolism of tolterodine in subjects with deficient CYP2D6 activity." Br J Clin Pharmacol 48 (1999): 564-72. [PMID: 10583027]
140 Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare "Centro de informacion online de medicamentos de la AEMPS - CIMA.".
141 Bedford TA, Rowbotham DJ "Cisapride: drug interactions of clinical significance." Drug Saf 15 (1996): 167-75. [PMID: 8879971]
142 Packer M "Combined beta-adrenergic and calcium-entry blockage in angina pectoris." N Engl J Med 320 (1989): 709-18. [PMID: 2564164]
143 Akdag I, Ersoy A, Kahvecioglu S, Gullulu M, Dilek K "Acute colchicine intoxication during clarithromycin administration in patients with chronic renal failure." J Nephrol 19 (2006): 515-7. [PMID: 17048210]
144 Product Information. Inspra (eplerenone). Searle, Chicago, IL.
145 Andrejak M, Hary L, Andrejak MT, Lesbre JP "Diltiazem increases steady state digoxin serum levels in patients with cardiac disease." J Clin Pharmacol 27 (1987): 967-70. [PMID: 3437068]
146 Product Information. Incivek (telaprevir). Vertex Pharmaceuticals, Cambridge, MA.
147 Product Information. Olysio (simeprevir). Janssen Pharmaceuticals, Titusville, NJ.
148 Product Information. Mycobutin (rifabutin). Pharmacia and Upjohn, Kalamazoo, MI.
149 Product Information. Adcetris (brentuximab vedotin). Seattle Genetics Inc, Bothell, WA.
150 Product Information. Pifeltro (doravirine). Merck & Company Inc, Whitehouse Station, NJ.
151 Product Information. Rescriptor (delavirdine). Pharmacia and Upjohn, Kalamazoo, MI.
152 Product Information. Agenerase (amprenavir). Glaxo Wellcome, Research Triangle Pk, NC.
153 Product Information. Rukobia (fostemsavir). ViiV Healthcare, Research Triangle Park, NC.
154 Product Information. Stribild (cobicistat/elvitegravir/emtricitabine/tenofov). Gilead Sciences, Foster City, CA.
155 Product Information. Aptivus (tipranavir). Boehringer-Ingelheim, Ridgefield, CT.
156 Product Information. Tivicay (dolutegravir). ViiV Healthcare, Research Triangle Park, NC.
157 Product Information. Intelence (etravirine). Ortho Biotech Inc, Bridgewater, NJ.
158 Product Information. Prezista (darunavir). Ortho Biotech Inc, Bridgewater, NJ.
159 Product Information. Selzentry (maraviroc). Pfizer U.S. Pharmaceuticals Group, New York, NY.
160 Olkkola KT, Palkama VJ, Neuvonen PJ "Ritonavir's role in reducing fentanyl clearance and prolonging its half-life." Anesthesiology 91 (1999): 681-5. [PMID: 10485779]
161 Product Information. Vaprisol (conivaptan). Cumberland Pharmaceuticals Inc, Nashville, TN.
162 Product Information. Samsca (tolvaptan). Otsuka American Pharmaceuticals Inc, Rockville, MD.
163 Product Information. Altabax (retapamulin topical). GlaxoSmithKline, Research Triangle Park, NC.
164 Product Information. Orladeyo (berotralstat). BioCryst Pharmaceuticals Inc, Durham, NC.
165 Product Information. Belsomra (suvorexant). Merck & Company Inc, Whitehouse Station, NJ.
166 Alderman CP, Gebauer MG, Gilbert AL, Condon JT "Possible interaction of zopiclone and nefazodone." Ann Pharmacother 35 (2001): 1378-80. [PMID: 11724087]
167 Backman JT, Olkkola KT, Aranko K, Himberg JJ, Neuvonen PJ "Dose of midazolam should be reduced during diltiazem and verapamil treatments." Br J Clin Pharmacol 37 (1994): 221-5. [PMID: 8198928]
168 Product Information. Hetlioz (tasimelteon). Vanda Pharmaceuticals Inc, Rockville, MD.
169 Product Information. Caplyta (lumateperone). Intra-Cellular Therapies, Inc., New York, NY.
170 Farkas D, Volak L, Harmatz J, von Moltke L, Court M, Greenblatt D "Short-term clarithromycin administration impairs clearance and enhances pharmacodynamic effects of trazodone but not of zolpidem." Clin Pharmacol Ther 85 (2009): 644-50. [PMID: 19242403]
171 Blakely KM, Drucker AM, Rosen CF "Drug-induced photosensitivity-an update: Culprit drugs, prevention and management." Drug Saf 42 (2019): 827-47. [PMID: 30888626]
172 Product Information. Zepzelca (lurbinectedin). Jazz Pharmaceuticals, Palo Alto, CA.
173 Product Information. Tagrisso (osimertinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
174 Product Information. Gavreto (pralsetinib). Blueprint Medicines Corporation, Cambridge, MA.
175 Product Information. Tabrecta (capmatinib). Novartis Pharmaceuticals, East Hanover, NJ.
176 Abernethy DR, Wesche DL, Barbey JT, et al. "Stereoselective halofantrine disposition and effect: concentration-related QTc prolongation." Br J Clin Pharmacol 51 (2001): 231-7. [PMID: 11298069]
177 Product Information. Zydelig (idelalisib). Gilead Sciences, Foster City, CA.
178 Product Information. Copiktra (duvelisib). Verastem, Inc., Needham, MA.
179 Product Information. Imbruvica (ibrutinib). Pharmacyclics Inc, Sunnyvale, CA.
180 Product Information. Iclusig (ponatinib). Ariad Pharmaceuticals Inc, Cambridge, MA.
181 Product Information. Koselugo (selumetinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
182 Product Information. Braftovi (encorafenib). Array BioPharma Inc., Boulder, CO.
183 Product Information. Ubrelvy (ubrogepant). Allergan Inc, Irvine, CA.
184 Product Information. Nurtec ODT (rimegepant). Biohaven Pharmaceuticals, New Haven, CT.
185 Product Information. Addyi (flibanserin). Sprout Pharmaceuticals, Raleigh, NC.
186 Hamberg P, Woo MM, Chen LC, et al. "Effect of ketoconazole-mediated CYP3A4 inhibition on clinical pharmacokinetics of panobinostat (LBH589), an orally active histone deacetylase inhibitor." Cancer Chemother Pharmacol 68 (2011): 805-13. [PMID: 21706316]
187 Product Information. Gilenya (fingolimod). Novartis Pharmaceuticals, East Hanover, NJ.
188 Product Information. Zeposia (ozanimod). Celgene Corporation, Summit, NJ.
189 Product Information. Istodax (romidepsin). Gloucester Pharmaceuticals, Cambridge, MA.
190 Product Information. Tasigna (nilotinib). Novartis Pharmaceuticals, East Hanover, NJ.
191 Product Information. Gleevec (imatinib mesylate). Novartis Pharmaceuticals, East Hanover, NJ.
192 Product Information. Sprycel (dasatinib). Bristol-Myers Squibb, Princeton, NJ.
193 Product Information. Meridia (sibutramine). Knoll Pharmaceutical Company, Whippany, NJ.
194 Product Information. Orlaam (levomethadyl acetate) Roxanne Laboratories Inc, Columbus, OH.
195 Product Information. Bextra (valdecoxib). Pharmacia Corporation, Peapack, NJ.
196 EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring.".
197 Product Information. Zejula (niraparib). Tesaro Inc., Waltham, MA.
198 Product Information. Butorphanol Tartrate (butorphanol). Apotex Corporation, Weston, FL.
199 Product Information. Buprenex (buprenorphine). Reckitt and Colman Pharmaceutical, Richmond, VA.
200 Hutchinson MR, Menelaou A, Foster DJ, Coller JK, Somogyi AA "CYP2D6 and CYP3A4 involvement in the primary oxidative metabolism of hydrocodone by human liver microsomes." Br J Clin Pharmacol 57 (2004): 287-97. [PMID: 14998425]
201 Product Information. Nuplazid (pimavanserin). Accelis Pharma, East Windsor, NJ.
202 Product Information. Xeglyze (abametapir topical). Dr. Reddy's Laboratories Inc, Upper Saddle River, NJ.
203 Product Information. Xenleta (lefamulin). Nabriva Therapeutics US, Inc., King of Prussia, PA.
204 Product Information. Zokinvy (lonafarnib). Eiger BioPharmaceuticals, Palo Alto, CA.
205 Product Information. Xtandi (enzalutamide). Astellas Pharma US, Inc, Deerfield, IL.
206 Product Information. Orgovyx (relugolix). Myovant Sciences, Inc., Brisbane, CA.
207 Franco-Salinas G, de la Rosette JJ, Michel MC "Pharmacokinetics and pharmacodynamics of tamsulosin in its modified-release and oral controlled absorption system formulations." Clin Pharmacokinet 49 (2010): 177-88. [PMID: 20170206]
208 Product Information. Rapaflo (silodosin). Watson Pharmaceuticals, Corona, CA.
209 Product Information. Duagen (dutasteride). GlaxoSmithKline Healthcare, Pittsburgh, PA.
210 Product Information. Afinitor (everolimus). Novartis Pharmaceuticals, East Hanover, NJ.
211 Product Information. Torisel (temsirolimus). Wyeth-Ayerst Laboratories, Philadelphia, PA.
212 Product Information. Rinvoq (upadacitinib). AbbVie US LLC, North Chicago, IL.
213 Product Information. Procardia (nifedipine). Pfizer US Pharmaceuticals, New York, NY.
214 DeVane CL, Nemeroff CB "Clinical pharmacokinetics of quetiapine - An atypical antipsychotic." Clin Pharmacokinet 40 (2001): 509-22. [PMID: 11510628]
215 Product Information. Stendra (avanafil). Vivus Inc, Mountain View, CA.
216 Product Information. Cialis (tadalafil). Lilly, Eli and Company, Indianapolis, IN.
217 Product Information. Oxbryta (voxelotor). Global Blood Therapeutics, Inc., South San Francisco, CA.
218 Product Information. Odomzo (sonidegib). Novartis Pharmaceuticals, East Hanover, NJ.
219 Aronson JK, Grahame-Smith DG "Clinical pharmacology: adverse drug interactions." Br Med J 282 (1981): 288-91. [PMID: 6779990]
220 Bergmann TK, Filppula AM, Launiainen T, Nielsen F, Backman J, Brosen K "Neurotoxicity and low paclitaxel clearance associated with concomitant clopidogrel therapy in a 60 year old Caucasian woman with ovarian carcinoma." Br J Clin Pharmacol (2015):. [PMID: 26446447]
221 Product Information. Tavalisse (fostamatinib). Rigel Pharmaceuticals, South San Francisco, CA.
222 Product Information. Cometriq (cabozantinib). Exelixis Inc, S San Francisco, CA.
223 Cakaloglu Y, Tredger JM, Devlin J, Williams R "Importance of cytochrome p-450IIIA activity in determining dosage and blood levels of FK 506 and cyclosporine in liver transplant recipients." Hepatology 20 (1994): 309-16. [PMID: 7519161]
224 Product Information. Orilissa (elagolix). AbbVie US LLC, North Chicago, IL.
225 Product Information. Clozaril (clozapine). Novartis Pharmaceuticals, East Hanover, NJ.
226 Product Information. Rythmol SR (propafenone). GlaxoSmithKline, Research Triangle Park, NC.
227 Kerin NZ, Aragon E, Faitel K, Frumin H, Rubenfire M "Long-term efficacy and toxicity of high- and low-dose amiodarone regimens." J Clin Pharmacol 29 (1989): 418-23. [PMID: 2661600]